Posts tagged Chemo Group
IntelGenx, Chemo Group expand partnership

IntelGenx (OTCQX:IGXT; TSX-V:IGX) strengthened its relationship with Chemo Group by signing a term sheet for co-development and commercialization of a generic tablet for the central nervous system (CNS) on a worldwide basis.

Read More
IntelGenx in licensing pact with Chemo Group

IntelGenx (OTCQX:IGXT; TSX-V:IGX) has entered into a licensing, development and supply agreement with closely-held Chemo Group, granting Chemo the exclusive license to commercialize two generic products for the U.S. market and one product on a worldwide basis.

The Chemo Group is a global pharmaceutical company with over 5,000 employees, operations in over 40 countries and annual revenue of more than $1.2-billion.

Read More